Introduction
Erythrocytosis is usually defined as a greater-than-two-standarddeviation increase from the age-, sex-and race-adjusted norm in hematocrit or hemoglobin level. 1 However, these laboratory parameters are affected by plasma volume and, therefore, the clinical impression of 'erythrocytosis' might (true erythrocytosis) or might not (apparent polycythemia) indicate a true increase in red cell mass (RCM). Apparent polycythemia results from either reduced plasma volume (relative polycythemia) or failure to recognize otherwise normal values for hematocrit or hemoglobin level that lie in the extreme right tail of the Gaussian distribution. Some investigators have advocated that the use of radioisotope techniques as a more accurate tool to assess RCM, and we acknowledge there are conceptual differences in this regard. [2] [3] [4] However, even if that were to be the case, result interpretation for an individual patient, without the knowledge of personal baseline value, remains inaccurate because of the statistically inevitable overlap of extreme values between subjects with and without disease.
The advent of relevant genetic tests and biological assays that reliably distinguish clonal from non-clonal erythrocytosis, 5 as well as the limited therapeutic relevance of distinguishing polycythemia vera (PV) from 'essential thrombocythemia with borderline increased hematocrit,' 6 has further undermined the value of RCM measurement. In the latter regard, a recent study of 1638 PV patients by the European Collaboration on Low-dose Aspirin in Polycythemia Vera group showed that a hematocrit in the range of 40-55% was not associated with the occurrence of thrombotic events, mortality or disease progression. 6 In other words, as long as treatment with low-dose aspirin is instituted, the value of aggressive phlebotomy to lower hematocrit levels below 45% in men and 42% in women is not based on hard evidence; that is the potential harm for not phlebotomizing a 'PV' patient with borderline high hematocrit (for example, 45-50%), who was inadvertently labeled as 'essential thrombocythemia,' is unsubstantiated. These were the salient points that were taken into account during the recent revision of the World Health Organization diagnostic criteria for PV. 7, 8 Accordingly, it is practically useful to define 'erythrocytosis' in an RCMindependent manner and yet consistent with thresholds used in the World Health Organization document: that is, hemoglobin 418.5 g/100 ml in men or 16.5 g/100 ml in women for Caucasians; or hemoglobin or hematocrit 499th percentile of method-specific reference range for age, sex and altitude of residence; or hemoglobin 417 g/100 ml in men or 15 g/100 ml in women for Caucasians (or the equivalent in other races and age groups) if associated with a documented and sustained increase of at least 2 g/100 ml from an individual's baseline value and cannot be attributed to correction of iron deficiency. 7 The purpose of the current review is to provide an overview of clinically relevant concepts on the mechanism of physiological and clonal erythropoiesis and to summarize recent developments in the genetic characterization of abnormal erythropoiesis. These are then translated into clinical algorithms and tables with practical values in approaching patients with erythrocytosis.
Physiological regulation of erythropoietin production
Tissue hypoxia results in a well-orchestrated response that takes place at multiple levels. The cellular response to hypoxia is controlled by a family of transcription factors, known as hypoxia-inducible factors (HIFs). HIF is a heterodimeric molecule, composed of two subunits, HIFa and HIFb (constitutively expressed aryl-hydrocarbon receptor nuclear translocator). There are three HIFa isoforms (HIF1a, HIF2a and HIF3a) that are synthesized continuously in response to hypoxia. [9] [10] [11] HIFs regulate the transcription of EPO and therefore erythropoietin (Epo) synthesis (Figure 1) . 12 Epo is needed for the effective differentiation and maturation of erythroid progenitors and is produced mainly by specialized peritubular fibroblast cells in the kidney. Recent studies point toward HIF2a as the principal isoform for the regulation of EPO expression.
In the presence of normoxia, HIFa is rapidly destroyed by the collaborative effect of oxygen, prolyl hydroxylase domain (PHD)-containing enzymes and the von Hippel-Lindau tumor suppressor protein (VHL) (Figure 1) . 15 There are three PHD isoenzymes (PHD1, PHD2 and PHD3), among which PHD2 is the key enzyme in catalyzing the prolyl hydroxylation of HIFa, using oxygen as a co-substrate. Hydroxylated HIFa can bind to VHL, and the HIFa-VHL complex facilitates ubiquitin-mediated proteasomal degradation of HIFa (Figure 1) . 16 Under conditions of tissue hypoxia, the proteasomal degradation of HIFa is slowed, resulting in its cytoplasmic accumulation and subsequent translocation to the nucleus, where it dimerizes with HIFb ( Figure 1 ). The two then bind to short DNA sequences that contain the hypoxia regulatory elements and regulate oxygendependent transcription of HIF target genes. 17 The products of these genes include Epo, transferrin, transferrin receptor, vascular endothelial growth factor and others. [17] [18] [19] HIF pathway molecule mutations have been associated erythrocytosis and/or tumors.
Epo-induced signaling
Binding of Epo to its receptor (EpoR) results in receptor homodimerization and autophosphorylation of the receptorassociated Janus kinase 2 (JAK2), a cytoplasmic protein tyrosine kinase ( Figure 2 ). Such an activation of JAK2 in turn mediates the phosphorylation of key tyrosine residues on the distal cytoplasmic region of EpoR, 20 which then serve as docking sites for downstream effectors, including signal transducer and activator of transcription protein 5 (STAT5) and phosphatidylinositol 3 kinase (PI3 kinase). Activated STAT5 homodimerizes and translocates to the nucleus to affect gene transcription. PI3 kinase phosphorylates and activates AKT serine threonine kinase as well as the GATA-1 transcription factor. 20, 21 The end result of EpoR signaling is promotion of effective erythropoiesis by way of both enhanced proliferation and reduced apoptosis through the upregulation of antiapoptotic proteins, such as BCL-x L . In PV, JAK-STAT is constitutively hyperactivated by the gain-offunction JAK2 mutation (Figure 2 ).
EpoR signaling is tightly regulated by at least three protein families: specific protein tyrosine phosphatases (PTP), SH2-containing suppressors of cytokine signaling (SOCS) and protein inhibitors of activated STAT (PIAS). For example, approximately 30 min after Epo binding, the Src homology phosphatase-1 (SHP-1) is recruited to EpoR and is able to dephosphorylate both EpoR and JAK2. 22 There are currently eight identified members of the SOCS gene family, but only four are physiologically characterized (CIS, SOCS-1, SOCS-2 and SOCS-3). 23 SOCS action includes direct binding to JAK2 with inhibition of kinase activity and facilitation of proteasomal degradation. 24 Lnk is an adaptor protein with an SH2 domain that is phosphorylated in the presence of Epo, and is able to block three important erythroid cell signaling pathways, namely, JAK/STAT, PI3 kinase/AKT and mitogen-activated protein kinase. 25 
Physiological role of hemoglobin in RCM regulation
Oxygen in blood is predominantly transported by hemoglobin, an iron-containing molecule that primarily assists with the process of gas exchange occurring at the alveolar-capillary The complete evaluation of erythrocytosis MM Patnaik and A Tefferi interface in the lungs and locally at the tissue level. The hemoglobin molecule is a tetramer consisting of four heme moieties and four globin chains. Oxygenation and deoxygenation of hemoglobin occurs at the heme iron site, and the binding and release of oxygen can be expressed by the sigmoid-shaped oxygen dissociation curve (Figure 3) . 26 The sigmoid shape of the curve delineates the interactive and cooperative manner of oxygen uptake and release in the lungs and at the tissue level.
Once oxygen is released at the tissue level, the deoxygenated hemoglobin molecule undergoes a conformational change, becoming stable in a tense state (T state). This T state increases the affinity of the hemoglobin molecule toward oxygen, allowing it to bind avidly to oxygen available at the pulmonary alveolar-capillary interface. Once the molecule gets oxygenated, it undergoes another conformational change to the relaxed state (R state), which in turn lowers its oxygen affinity, allowing the oxygen to dissociate easily once it reaches the tissue sites. Hemoglobin oxygen affinity is affected by several factors, including blood pH, levels of 2,3-bisphosphoglycerate (2,3-BPG), hemoglobin structure and temperature ( Figure 3) . Shifting of the curve left ward indicates a higher affinity of the hemoglobin molecule to oxygen and vice versa. Conditions that shift the oxygen dissociation curve to the left can be associated with erythrocytosis and include high-oxygen-affinity hemoglobinopathies and low levels of 2,3-BPG.
Classification of erythrocytosis
It is practically useful to classify erythrocytosis as being congenital or acquired (Table 1) . Congenital erythrocytosis includes patients with known germline mutations that result in enhanced Epo effect (for example, EpoR mutations), altered intracellular oxygen sensing (for example, mutations involving the von Hippel-Lindau tumor suppressor gene) or decreased P50 (for example, high-oxygen-affinity hemoglobinopathy). P50 is the partial pressure of oxygen in blood at which 50% of the hemoglobin is saturated with oxygen. Acquired erythrocytosis can be subclassified into clonal or acquired secondary erythrocytosis. PV is the sole cause of clonal erythrocytosis. The most frequent cause of acquired secondary erythrocytosis is tissue hypoxia resulting from a variety of conditions, including those listed in Tables 1 and 2 .
We did not list 'idiopathic erythrocytosis (IE)' in Table 1 for several reasons. The term IE is usually used to connote increased RCM of 'unknown' cause. However, most of the literature references to IE are flawed and overlook the fact that it is difficult to ascertain an increased RCM in an individual patient without knowledge of personal baseline value. In other words, some patients who are assigned the diagnosis of IE might represent otherwise healthy persons whose RCM readings lie in the right extreme tail of the Gaussian distribution. Also, the term IE is . Activated JAK2 in turn mediates the phosphorylation of key tyrosine residues on the distal cytoplasmic region of EpoR, which then serve as docking sites for downstream effectors, including signal transducer and activator of transcription protein 5 (STAT5) and phosphatidylinositol 3 kinase (PI3 kinase). Activated STAT5 homodimerizes and translocates to the nucleus to affect gene transcription. In polycythemia vera, JAK-STAT is constitutively hyperactivated by gain-of-function JAK2 mutation.
The complete evaluation of erythrocytosis MM Patnaik and A Tefferi sometimes inappropriately used despite the presence of laboratory evidence for clonal erythrocytosis (for example, JAK2 exon 12 mutation, subnormal serum Epo level and endogenous erythroid colonies). Our position on the matter is that one has to document full diagnostic evaluation for both clonal and congenital polycythemia before resorting to a diagnosis of IE. Furthermore, with the decreasing use of RCM measurement in routine clinical practice, the term IE, as we know it today, might become obsolete. This is not meant to undermine the possibility of well-documented, but otherwise unexplained, erythrocytosis in certain instances, but instead to highlight the need for full evaluation and avoidance of the cavalier use of the term.
Causes of congenital erythrocytosis
Associated with decreased P50 High-oxygen-affinity hemoglobinopathies. High-oxygenaffinity hemoglobins release oxygen at a lower-than-normal rate and thus create relative tissue hypoxia, which might result in compensatory erythrocytosis in approximately a third of affected patients. Hemoglobin Chesapeake was the first high-oxygenaffinity hemoglobin variant to be identified as a cause of erythrocytosis. 27 Since then, many more high-affinity structural variants of hemoglobin have been described, including hemoglobins Malmo and San Diego (http://globin.bx.psu.edu/hbvar/). Most of the high-oxygen-affinity mutations involve the b-globin chain and a 1 b 2 contact zones. 28 Affected patients often present with isolated erythrocytosis, in the absence of signs and symptoms of systemic disease. These patients often may have family members who are similarly affected.
High-oxygen-affinity hemoglobinopathies display decreased P50. 26, 29 The P50 value can either be directly measured using a co-oximeter or be calculated using a mathematical formula log PO2(7.4) ¼ log PO2(observed)À[0.5(7.4ÀpH(observed))].
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The P50 of a healthy person with normal hemoglobin is 26±1.3 mm Hg, with the 99% confidence interval for individual observations estimated to be between 22.6 and 29.4 mm Hg. Structurally abnormal high-affinity hemoglobin should be suspected if the P50 level is o20 mm Hg. Conventional hemoglobin electrophoresis techniques are not adequate to characterize high-oxygen-affinity hemoglobin variants. 28 Additional studies using reversed-phase high-performance liquid chromatography or globin gene sequencing might be necessary for identification. 28 Transmission in affected patients is usually autosomal dominant. Serum Epo levels are either normal or elevated. 29 Bisphosphoglycerate mutase deficiency. 2,3-Bisphosphoglycerate is synthesized in red blood cells via the Rappaport Luebering shunt, which involves the conversion of 1,3-BPG to 2,3-BPG, a reaction that is catalyzed by the enzyme bisphosphoglycerate mutase (BPGM). 2,3-BPG then binds to the central cavity of the hemoglobin tetramer and allosterically changes the hemoglobin molecule into a low-oxygen-affinity state (that is, shifts the oxygen dissociation curve to the right). 2,3-BPG deficiency results in the opposite effect and is often the result of decreased BPGM activity. 2,3-BPG deficiency-associated erythrocytosis is extremely rare and often results from mutations involving BPGM. [31] [32] [33] Transmission of the fully penetrant clinical phenotype was autosomal recessive and clinical presentation limited to isolated erythrocytosis with normal serum Epo level. Diagnosis is established by showing a low P50, a normal hemoglobin structure and decreased 2,3-BPG/ BPGM activity. 31 Methemoglobinemia. Methemoglobinemia is clinically suspected when cyanosis is accompanied by normal PaO2 levels but low saturation per pulse oximeter. 34 New-generation eightwavelength pulse oximeters are capable of measuring both carboxyhemoglobin and methemoglobin. Methemoglobin is formed when heme Fe þ 2 is oxidized to heme Fe 35 Physiological forms of methemoglobin are reduced to maintain the methemoglobin level o2%, by the NADH-methemoglobin reductase system, which includes two enzymes: cytochrome b5 and cytochrome b5 reductase (b5R). 36 Congenital methemoglobinemias are of three main types: the autosomal recessive cytochrome b5R deficiency (the most common), 35 cytochrome b5 deficiency and the autosomal dominant hemoglobin M disease. 37 Associated with normal P50 VHL mutations including Chuvash polycythemia. Chuvash polycythemia is a rare, autosomal recessive, congenital erythrocytosis. The disease was first described in the Chuvash autonomous region in Russia, 38 but genetically, Chuvash-type congenital polycythemia occurs in other racial and ethnic groups. 39, 40 Affected patients are homozygous for a germline mutation affecting the VHL tumor suppressor gene, VHL 598C4T, producing an abnormal R200W (arginine to tryptophan) VHL protein. 41, 42 This abnormal VHL protein can no longer combine with the HIFa proteins, thus impairing their proteasomal degradation. 43 In contrast to patients with the VHL disease, an autosomal dominant familial cancer syndrome, patients with Chuvash polycythemia do not display an increased predilection for tumors.
The clinical phenotype of Chuvash polycythemia includes erythrocytosis, increased serum Epo level, varicose veins, lower blood pressure, and premature mortality from arterial and venous thrombotic events. 44 Serum plasminogen activator inhibitor (PAI-1) levels have been found to be elevated in patients with Chuvash polycythemia, possibly explaining the higher-than-normal incidence of thrombosis in these patients. 44 It is to be recalled that PAI-1 is an HIFa-regulated gene. However, patients with Chuvash polycythemia also display altered cytokine profiles, 45 as well as other changes, such as increased serum homocysteine, 46 that might play a part in their increased risk for thrombotic complications.
Homozygous, compound heterozygous or simple heterozygous germline mutations of the VHL gene, other than those associated with Chuvash polycythemia, have been identified in rare patients with congenital polycythemias (for example, VHL 235C-T, VHL 562C-G and VHL 523-G). 47, 48 These patients also tend to present with isolated erythrocytosis and markedly elevated Epo levels. 47, [49] [50] [51] Also, erythrocytosis is occasionally seen in patients with VHL syndrome; in this case, however, the erythrocytosis is a paraneoplastic manifestation of the tumors associated with the disease and not an actual manifestation of the syndrome itself. 52 In most of these cases, erythrocytosis has been found to subside with treatment or removal of the tumor.
VHL syndrome is an autosomal dominant familial tumor syndrome caused by the inactivation of the VHL tumor suppressor gene. Patients affected by this multisystem disorder inherit one germline mutation and acquire another somatic mutation of the VHL gene, resulting in tumorigenesis. 53 Heterozygotes are at an increased risk for developing cerebellar and retinal hemangioblastomas, clear-cell renal cell carcinomas, pheochromocytomas, pancreatic neuroendocrine tumors and endolymphatic sac tumors. The mutations identified in patients with congenital erythrocytosis that involve the VHL gene lie outside the a-and b-domains of the VHL protein, and do not interfere with the function of VHL protein as a tumor suppressor molecule.
42

PHD2 mutations. Under normoxic conditions, PHD2
hydroxylates HIFa proteins, thus facilitating VHL binding and subsequent ubiquitin-mediated proteasomal degradation. Rare cases of erythrocytosis-associated PHD2 mutations have been described, including heterozygous PHD2 950C4G mutation resulting in P317R 54 and 1112G4A resulting in R371H, 55 both with the loss of PHD2 function. Serum Epo was normal in both instances and in another report of three cases with erythrocytosis-associated PHD2 mutations, including 606delG resulting in Met2O2IlefsX71, 840_841insA resulting in Arg281ThrfsX3 and 1129C4T resulting in Gln377X. 56 Also recently, another PHD2 mutation (1121A4G resulting in H374R) was associated with both erythrocytosis and recurrent paraganglioma; 57 the particular mutation was associated with loss of heterozygosity of the PHD2 region, suggesting a tumor suppressor function for the PHD2 gene.
57
HIF2a mutations. As mentioned before, HIF is a transcription factor that activates hypoxia-inducible genes, such as Epo. A heterozygous HIF2a 1609G4T mutation in exon 12 of the HIF2a gene, resulting in G537W, was recently described in a family with erythrocytosis.
14 Three patients from the affected family, including the index case, displayed erythrocytosis, increased serum Epo level and the absence of systemic symptoms. 14 The authors were also able to show an impaired mutant HIF2a-PHD2 interaction. The same group of investigators has subsequently reported two additional heterozygous HIF2A mutations in four additional patients (all with elevated serum Epo levels) with congenital erythrocytosis. 58 The new mutations included 1603A4G resulting in M535V in one patient and 1609G4A mutation resulting in G537A in three patients. Another HIF2a mutation (1605G4A resulting in M535I) was also recently reported in association with asymptomatic erythrocytosis and normal or elevated serum Epo level. 59 EpoR mutations. EpoR signaling is regulated by the binding of SHP-1 (or other JAK/STAT regulators) to the distal cytoplasmic region of EpoR. This interaction results in the downregulation of the Epo-mediated activation of the JAK2/STAT5 pathway. 60 To date, close to 16 germline EPOR mutations (all in exon 8) that cause erythrocytosis have been described. 61, 62 These mutations often result in cytoplasmic truncation of EpoR, resulting in a loss of the aforementioned C-terminal negative regulatory domain. Transmission is usually autosomal dominant. Affected patients are usually asymptomatic and display subnormal (or normal) serum Epo level and hypersensitivity of erythroid progenitors to exogenous Epo.
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Causes of acquired erythrocytosis
Reactive physiologically appropriate erythrocytosis in response to hypoxia Chronic hypoxia gives rise to secondary erythrocytosis, so as to compensate for the low oxygen concentrations available either at the pulmonary, and/or at the tissue level. The clinical interpretation of arterial blood gases, pulmonary function tests and chest radiography is an important adjunct to help make a reliable diagnosis. Table 2 details the causes and evaluation for conditions that can give rise to chronic hypoxemia with erythrocytosis.
Pathological/inappropriate production of Epo
Some malignant and non-malignant tumors have been shown to produce Epo inappropriately. A high expression of EPO mRNA in the tumor tissue and the correction of erythrocytosis, with a fall in the serum Epo levels, once the tumor has been removed, serve to establish the link between the tumor and the associated secondary erythrocytosis. Tumors that have been associated with an inappropriate Epo production include cerebellar hemangioblastomas, 65 uterine leiomyomas, 66 pheochromocytoma, 67 renal cell carcinoma, 68,69 hepatocellular carcinoma, 70 parathyroid adenomas 71 and meningiomas. 72 
Polycythemia vera
Polycythemia vera is a clonal stem cell disease with trilineage myeloid involvement. 73 In vitro, erythroid colony formation in patients with PV does not require the addition of exogenous Epo. 74 This phenomenon is called endogenous erythroid colony growth and does not occur in either healthy persons or patients with non-clonal erythrocytosis. The EpoR gene as well as its protein is intact in PV. 75 On the other hand, several postreceptor molecular abnormalities have been reported and include increased baseline phosphorylation of the IGF-1 receptor, 76 decreased activity of SH-PTP1 (a tyrosine phosphatase), 77 increased activity of membrane-associated SH-PTP, 78 constitutive activation of STAT3, 79 upregulation of negative control elements of the cell cycle (p16/p14) 80 and abundance, in erythroid precursors, of antiapoptotic proteins (Bcl-x L ). 81 The molecular pathogenesis of PV remained elusive until early 2005 [82] [83] [84] [85] when several groups reported a JAK2 gain-offunction mutation (JAK2V617F) in PV (Figure 2) , essential thrombocythemia and primary myelofibrosis. In 2006, a GOF thrombopoietin receptor (MPL) mutation (MPLW515L) was reported in JAK2V617F-negative primary myelofibrosis. 86 In 2007, other JAK2 mutations (exon 12 mutations) in JAK2V617F-negative patients with PV were described. 87 Additional MPL and JAK2 exon 12 mutations have since been added to the list, but the PV phenotype has been associated with the latter and not the former.
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Evaluation of a patient with erythrocytosis Figure 4 outlines a contemporary algorithm for evaluating a patient with erythrocytosis. The key to a successful approach lies in establishing upfront whether or not the erythrocytosis is secondary or clonal (that is, PV). The decision to pursue the possibility of PV is not automatic and depends on the clinical index of suspicion and the pretest probability. Increased RCM in PV patients is Epo independent and is usually accompanied by subnormal serum Epo level. 91, 92 However, the presence of normal Epo level does not rule out the diagnosis of PV although an increased serum Epo level makes the diagnosis very unlikely. In contrast, patients with secondary erythrocytosis display either elevated or normal serum Epo level. In addition, it is now well established that virtually all PV patients carry a JAK2 mutation that is readily detected in the peripheral blood. Accordingly, it is reasonable to begin diagnostic evaluation of the patient with erythrocytosis by screening peripheral blood for JAK2V617F (that is, the JAK2 mutation that is present in 97% of patients with PV) and measuring serum Epo levels (Figure 4 ).
Scenario 1: JAK2V617F positivity associated with subnormal serum Epo level
If the results of both tests are consistent with PV (that is, the mutation is detected and serum Epo level is subnormal), then the diagnosis of PV is confirmed and the patient also fulfills the World Health Organization diagnostic criteria for PV (Table 3) .
Scenario 2: JAK2V617F positivity associated with normal or elevated serum Epo level
In a JAK2V617F-positive patient with erythrocytosis but normal or elevated serum Epo level, the results of the mutation analysis need to be reviewed, and repeated if necessary, to avoid false-positive molecular test results. If the repeat tests remain unchanged, then the patient needs demonstration of either PV-consistent bone marrow histology (that is, increased cellularity, loose megakaryocytic clusters and megakaryocytic pleomorphism) or endogenous erythroid colony growth to meet World Health Organization criteria for PV diagnosis (Table 3 ).
Scenario 3: JAK2V617F negativity associated with subnormal serum Epo level
If the patient under evaluation is negative for JAK2V617F, then the possibility of a JAK2 exon 12 mutation is entertained, but only in the presence of subnormal serum Epo level ( Figure 4 ). This is because JAK2 exon 12 mutations are almost always associated with subnormal serum Epo level. If both JAK2V617F and JAK2 exon 12 mutations are negative in a patient with subnormal serum Epo level, the possibility of EpoR mutationassociated congenital erythrocytosis should be considered (Figure 4) . This scenario is not consistent with PV. However, the results of molecular testing do not necessarily override sound clinical judgment, and if one still suspects PV based on clinical grounds, then one should consider additional tests to further inquire about the possibility of PV, including bone marrow examination, 93 cytogenetic studies (chromosomal abnormalities are seen in approximately 10-20% of patients with PV at the time of diagnosis) 94 and specialized biological assays, such as endogenous erythroid colony growth.
Once PV is excluded from the differential diagnosis of erythrocytosis, the next question becomes whether or not the erythrocytosis is acquired, of unknown duration or lifelong. Tables 1 and 2 provide lists of differential diagnosis for acquired secondary erythrocytosis and suggested laboratory testing for approaching erythrocytosis associated with central or peripheral hypoxia. Inappropriate Epo production, as in Epo-secreting tumors, is suspected in the presence of markedly elevated serum Epo levels. Computed tomography of the head, chest, abdomen and pelvis facilitates detection of these tumors.
When erythrocytosis is either life-long or if its duration cannot be determined, especially in younger individuals, the possibility of congenital polycythemia must be considered. In this regard, it is reasonable to begin the work-up with measurement of P50 (the oxygen tension at which hemoglobin is 50% saturated). Decreased P50 suggests the presence of high-oxygen-affinity hemoglobinopathy, 2,3-BPG deficiency or, in the presence of cyanosis, methemoglobinemia (Table 1 and Figure 4 ). If P50 is normal, then the possibility of VHL mutations should be considered first because they constitute the most frequent mutations in congential polycythemia. Mutations involving other molecules in the cellular oxygen-sensing system (that is, HIFa and PHD2 mutations) are extremely rare, and their evaluation for now is restricted to research laboratories. Nevertheless, it is clinically useful to note that reported cases of VHL and HIFa mutations were associated with increased serum Epo and PHD2 mutations with normal serum Epo levels.
Conclusion
The seminal discovery of JAK2V617F and other JAK2 mutations in almost all patients with PV has substantially affected our current approach to erythrocytosis. In JAK2 mutation-negative erythrocytosis, the absence of subnormal serum Epo level makes the possible diagnosis of PV highly unlikely. The differential diagnosis of non-clonal erythrocytosis is vast, and it is best to first determine the duration of the process and differentiate between life-long and acquired erythrocytosis. Important discoveries in the molecular pathogenesis of congenital polycythemia have somewhat simplified the approach to congenital polycythemia, but many such cases currently remain unexplained. Recent reports on the occurrence of secondary erythrocytosis in patients with renal cell carcinoma, melanoma or hepatocellular carcinoma, being treated with tyrosine kinase inhibitors, such as sunitinib and sorafenib, 95 raise the prospect of novel mechanistic explanations for some of these instances. Regardless, during routine clinical practice, it is important to be familiar with 'known' causes of both acquired and congenital polycythemia so that an objective and practical approach to diagnosis can be developed.
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